Cargando…

Natalizumab concentrations during pregnancy in three patients with multiple sclerosis

In women with very active multiple sclerosis (MS), natalizumab can be continued during pregnancy to prevent rebound disease activity. Our aim was to evaluate changes in serum natalizumab trough concentrations during pregnancy. Blood samples of 3 patients were collected before, during, and after preg...

Descripción completa

Detalles Bibliográficos
Autores principales:	Toorop, Alyssa A, Rispens, Theo, Strijbis, Eva MM, van Oosten, Bob W, de Jong, Brigit A, Uitdehaag, Bernard MJ, Killestein, Joep, van Kempen, Zoé LE
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Case Report and Clinical Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8795211/ https://www.ncbi.nlm.nih.gov/pubmed/34931887 http://dx.doi.org/10.1177/13524585211052168

Ejemplares similares

Fingerprick blood samples to measure serum natalizumab concentrations
por: Toorop, Alyssa A, et al.
Publicado: (2022)

Response to “Letter to the editor on the paper: The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing”
por: van Kempen, Zoé LE, et al.
Publicado: (2017)

Disease activity following pregnancy-related discontinuation of natalizumab in MS
por: Kleerekooper, Iris, et al.
Publicado: (2017)

Infusion-related events during natalizumab: No need for post-infusion monitoring
por: Loonstra, Floor C, et al.
Publicado: (2019)

Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic
por: van Lierop, Zoë YGJ, et al.
Publicado: (2021)

Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients
por: Leurs, Cyra E, et al.
Publicado: (2017)

The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing
por: van Kempen, Zoé LE, et al.
Publicado: (2017)

Serum glial fibrillary acidic protein in natalizumab-treated relapsing-remitting multiple sclerosis: An alternative to neurofilament light
por: Wessels, Mark HJ, et al.
Publicado: (2023)

Neurofilament-light and contactin-1 association with long-term brain atrophy in natalizumab-treated relapsing-remitting multiple sclerosis
por: van Lierop, Zoë YGJ, et al.
Publicado: (2022)

Mild progressive multifocal leukoencephalopathy after switching from natalizumab to ocrelizumab
por: Toorop, Alyssa A., et al.
Publicado: (2020)

Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients
por: van Lierop, ZYGJ, et al.
Publicado: (2021)

Ocrelizumab Concentration Is a Good Predictor of SARS‐CoV‐2 Vaccination Response in Patients with Multiple Sclerosis
por: van Kempen, Zoé L. E., et al.
Publicado: (2022)

Serum contactin-1 as a biomarker of long-term disease progression in natalizumab-treated multiple sclerosis
por: van Lierop, Zoë YGJ, et al.
Publicado: (2021)

Emerging safety issues in alemtuzumab-treated MS patients
por: Killestein, Joep, et al.
Publicado: (2019)

The association between blood MxA mRNA and long-term disease activity in early multiple sclerosis
por: Coerver, Eline M. E., et al.
Publicado: (2022)

Severe breakthrough COVID-19 after SARS-CoV-2 booster vaccination in an MS patient on ocrelizumab
por: van Kempen, Zoé L.E., et al.
Publicado: (2022)

Neuroaxonal and Glial Markers in Patients of the Same Age With Multiple Sclerosis
por: Loonstra, Floor C., et al.
Publicado: (2022)

Personalized monitoring of ambulatory function with a smartphone 2-minute walk test in multiple sclerosis
por: Lam, Ka-Hoo, et al.
Publicado: (2023)

Cerebrospinal fluid mtDNA concentration is elevated in multiple sclerosis disease and responds to treatment
por: Leurs, Cyra E, et al.
Publicado: (2017)

COVID-19 in multiple sclerosis: The Dutch experience
por: Loonstra, Floor C, et al.
Publicado: (2020)

Retinal atrophy in relation to visual functioning and vision-related quality of life in patients with multiple sclerosis
por: Balk, Lisanne J, et al.
Publicado: (2017)

Concomitant granule cell neuronopathy in patients with natalizumab-associated PML
por: Wijburg, Martijn T., et al.
Publicado: (2016)

Neurophysiological MEG markers of cognitive impairment and performance validity in multiple sclerosis
por: Simon, Shira, et al.
Publicado: (2023)

4-aminopyridine is not just a symptomatic therapy, it has a neuroprotective effect – Yes
por: Strijbis, Eva MM, et al.
Publicado: (2020)

Cognitive impairment in patients with multiple sclerosis is associated with atrophy of the inner retinal layers
por: Coric, Danko, et al.
Publicado: (2017)

Association of Arachidonic Acid–Derived Lipid Mediators With Disease Severity in Patients With Relapsing and Progressive Multiple Sclerosis
por: Broos, Jelle Y., et al.
Publicado: (2023)

Keep your eyes on the prize: Tackling breakthrough COVID-19 in MS patients
por: van Kempen, Zoé LE, et al.
Publicado: (2021)

Adipokines in multiple sclerosis patients are related to clinical and radiological measures
por: Loonstra, Floor C., et al.
Publicado: (2022)

Natalizumab concentrations during pregnancy in three patients with multiple sclerosis: A clinical commentary
por: Dobson, Ruth, et al.
Publicado: (2022)

Asymptomatic spinal cord lesions do not predict the time to disability in patients with early multiple sclerosis
por: Dekker, Iris, et al.
Publicado: (2017)

Smartphone‐derived keystroke dynamics are sensitive to relevant changes in multiple sclerosis
por: Lam, Ka‐Hoo, et al.
Publicado: (2021)

Longitudinal SARS-CoV-2 humoral response in MS patients with and without SARS-CoV-2 infection prior to vaccination
por: van Dam, Koos P. J., et al.
Publicado: (2022)

Disease severity classification using passively collected smartphone-based keystroke dynamics within multiple sclerosis
por: Hoeijmakers, Aleide, et al.
Publicado: (2023)

Extended interval dosing of ocrelizumab modifies the repopulation of B cells without altering the clinical efficacy in multiple sclerosis
por: Rodriguez-Mogeda, Carla, et al.
Publicado: (2023)

Functional brain network organization measured with magnetoencephalography predicts cognitive decline in multiple sclerosis
por: Nauta, Ilse M, et al.
Publicado: (2020)

The Use of Smartphone Keystroke Dynamics to Passively Monitor Upper Limb and Cognitive Function in Multiple Sclerosis: Longitudinal Analysis
por: Lam, Ka-Hoo, et al.
Publicado: (2022)

Interferons and Natalizumab for Multiple Sclerosis
por: Clar, Christine, et al.
Publicado: (2008)

Natalizumab in the treatment of multiple sclerosis
por: Brown, Brandon A
Publicado: (2009)

The use of natalizumab for multiple sclerosis
por: Brandstadter, Rachel, et al.
Publicado: (2017)

Natalizumab Rebound in Multiple Sclerosis
por: Lee, Joshua D., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gheg90gub6lgucqg583vpb05ra